Trial
NCT02119650
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
NSCLC (Non-small Cell Lung Carcinoma)
Intervention
Ruxolitinib
Why stopped
The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-13